Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reloxaliase in Enteric Hyperoxaluria (URIROX-2)
NCT03847090Phase 3Terminated
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Replacement Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of reloxaliase in enteric hyperoxaluria (EH), sponsored by Allena Pharmaceuticals, Inc.. Started Aug 2019; status: terminated.
02
Drugs
reloxaliase
03
Conditions
enteric hyperoxaluria (EH)
Beyond the preview
Go deeper on NCT03847090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847090.